Bavarian Nordic has secured a DKK 200 million+ vaccine contract in Europe, bringing total public‑preparedness deals to over ...

Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from ...

Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from non-European countries, the Company has now secured above DKK 3,000 millio ...

The expiration of shots the Biden administration promised to send comes after President Donald Trump cut deeply into foreign aid.

Paul Chaplin, President & CEO of Bavarian Nordic, said: “ Through partnerships we have made significant advances already by expanding access to our mpox vaccine for children and adolescents.

View the latest Bavarian Nordic A/S ADR (BVNRY) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Yap Boum, PhD, MPH, deputy incident manager for Africa CDC's mpox response, said Mozambique's three cases involve two men and ...

Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

In Europe, the Stoxx Europe 600 gained 0.4% in morning trading. Bavarian Nordic added 5.4% and Anglo American rose 4.1%. On the other hand, Grafton Group slipped 7.5%, and Barry Callebaut lost 7.2%.

Review the current Bavarian Nordic AS (BAVA:XCSE) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if BAVA is the best investment for you.

Bavarian Nordic AS Bavarian Nordic AS BAVA Stock XCSE Rating as of Jun 24, 2025 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends ...